EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HiMSC and EV derived treatments increase Quality of Life and reduce amount of Knee Replacement Surgeries compared to current standard of care for knee osteoarthritis patients in The Netherlands

Iris W A Boot iD, Georgina Shaw, Yolande F M Ramos iD, Mary Murphy, Ingrid Meulenbelt, Hubertus J M Vrijhoef, AutoCRAT consortium

PLOS One · 26.03.2026 · 21 (3) · e0344203

DOI: 10.1371/journal.pone.0344203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 26.03.2026. Verfasst von Iris W A Boot und 6 weiteren Autor:innen. Beteiligte Einrichtung: Panaxea b.v., Den Bosch, The Netherlands. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Knee, Osteoarthritis, Knee, Quality of Life, Extracellular Vesicles. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, Dutch Arthritis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Current osteoarthritis treatments are designed to reduce pain and improve mobility instead of promoting the regeneration of cartilage. Cell-based therapies are being developed for the treatment of osteoarthritis. The aim of this study was to assess the cost-effectiveness of mesenchymal stromal cells and extracellular vesicle treatments compared to standard of care for patients with Kellgren-Lawrence stage II knee osteoarthritis in the Netherlands, from a hospital and societal perspective.

Design

A Markov model was developed to assess the 40-year incremental cost-effectiveness ratio of mesenchymal stromal cells and/or extracellular vesicle treatments produced by automated or manual production methods, compared to standard of care. Secondary outcomes were amount of total knee replacement and total knee replacement revision surgeries. In addition, one-way sensitivity analyses and scenario analyses were performed.

Results

The incremental cost-effectiveness ratios from a hospital perspective were -€10,982.10 for automatically produced mesenchymal stromal cells, -€9,301.79 for manually produced mesenchymal stromal cells, -€12,793.17 for automatically produced mesenchymal stromal cells and extracellular vesicle, and -€11,998.02 for manually produced mesenchymal stromal cells and extracellular vesicle versus standard of care. From the societal perspective incremental cost-effectiveness ratios were €68,870.58 for automatically produced mesenchymal stromal cells, -€67,280.27 for manually produced mesenchymal stromal cells, -€70,771.65 for automatically produced mesenchymal stromal cells and extracellular vesicle, and -€69,976.50 for manually produced mesenchymal stromal cells and extracellular vesicle versus standard of care. The amount of total knee replacement surgeries per 1,000 patients was 426 for the cell treatment groups, and 609 for the standard of care group, and 19 and 30 total knee replacement revision surgeries, respectively.

Conclusions

This model, inherent to its assumptions, shows that hiMSC and EV treatments are cheaper and more effective for patients with knee osteoarthritis, from both perspectives. Moreover, they are expected to lower the number of surgeries. These conclusions persist among all scenario analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, KneeOsteoarthritis, KneeQuality of LifeExtracellular VesiclesMesenchymal Stem Cell TransplantationStandard of CareMesenchymal Stem CellsNetherlandsHumansCost-Benefit AnalysisCost-Effectiveness AnalysisMarkov Chains

Autor:innen und Institutionen

  • Panaxea b.v., Den Bosch, The Netherlands.
  • University of Galway, Galway, Ireland.
  • Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Iris W A Boot, Yolande F M Ramos

Förderung

  • Horizon 2020
  • Dutch Arthritis Society

Zitieren

APA

Boot, I. W. A., Shaw, G., Ramos, Y. F. M., Murphy, M., Meulenbelt, I., Vrijhoef, H. J. M., & AutoCRAT consortium (2026). HiMSC and EV derived treatments increase Quality of Life and reduce amount of Knee Replacement Surgeries compared to current standard of care for knee osteoarthritis patients in The Netherlands. PLOS One, 21(3), e0344203. https://doi.org/10.1371/journal.pone.0344203

Vancouver

Boot IWA, Shaw G, Ramos YFM, Murphy M, Meulenbelt I, Vrijhoef HJM, et al. HiMSC and EV derived treatments increase Quality of Life and reduce amount of Knee Replacement Surgeries compared to current standard of care for knee osteoarthritis patients in The Netherlands. PLOS One. 2026;21(3):e0344203. doi:10.1371/journal.pone.0344203

BibTeX
@article{Boot2026,
  author = {Boot, Iris W A and Shaw, Georgina and Ramos, Yolande F M and Murphy, Mary and Meulenbelt, Ingrid and Vrijhoef, Hubertus J M and AutoCRAT consortium, AutoCRAT consortium},
  title = {HiMSC and EV derived treatments increase Quality of Life and reduce amount of Knee Replacement Surgeries compared to current standard of care for knee osteoarthritis patients in The Netherlands},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {e0344203},
  doi = {10.1371/journal.pone.0344203}
}
Kostenlos starten →